Anticorps Monoclonal anti-TRAIL/CD253

TRAIL/CD253 Monoclonal Antibody for WB, IHC, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain

Applications

WB, IHC, IF, ELISA

Conjugaison

Non conjugué

Publications(3)

CloneNo.

1B9B4

N° de cat : 66756-1-Ig

Synonymes

TNFSF10, TRAIL, 1B9B4, Apo-2 ligand, CD253

---

Galerie de données de validation

• 

  WB analysis of human milk using 66756-1-Ig

  human milk were subjected to SDS PAGE followed by western blot with 66756-1-Ig (TRAIL antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human tonsillitis using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human tonsillitis using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Applications testées

• Résultats positifs en WB: tissu de lait humain
• Résultats positifs en IHC: tissu d'amygdalite humain, tissu de cancer de la prostate humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:2000
• Immunohistochimie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 1 publications below
• IF: See 1 publications below

Informations sur le produit

66756-1-Ig cible TRAIL/CD253 dans les applications de WB, IHC, IF, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: TRAIL/CD253 Protéine recombinante Ag25746
• Nom complet: tumor necrosis factor (ligand) superfamily, member 10
• Masse moléculaire calculée: 281 aa, 33 kDa
• Poids moléculaire observé: 28-30 kDa
• Numéro d’acquisition GenBank: BC032722
• Symbole du gène: TRAIL
• Identification du gène (NCBI): 8743
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine G
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

TNFSF10/TRAIL (tumor necrosis factor superfamily member 10) is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TNFSF10 induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.

Publications

Species	Application	Title
human		Adv Healthc Mater; TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).; Authors - Huan Hou
human	WB	Cancers (Basel); Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.; Authors - Changhong Ke
human	IF	Front Bioeng Biotechnol; The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma; Authors - Tian Xue

{{ptg:RelatedPrimaryAntibodies}}